Trends in Molecular Medicine · 2006 · 104 citations · 40 references
MedicineInfectious DiseasesPharmacologyBiochemical PharmacologyEnzymologyMolecular PharmacologyAntiparasitic AgentsAntiparasitic Drug ResistanceEnzyme InhibitionMalariaMolecular Basis Of ResistanceProtozoan Host-parasite InteractionsAntimalarial AgentsAntimalarial ChemotherapyAntimalarial Drug CombinationsArtemisinin ResistanceMalaria ParasitesMalaria ResistancePlasmodium FalciparumTreatment Of Malaria
There are more than half a billion cases of malaria every year. Combinations of an artemisinin with other antimalarial drugs are now recommended treatments for Plasmodium falciparum malaria in most endemic areas. These treatment regimens act rapidly to relieve symptoms and effect cure. There is considerable controversy on how artemisinins work and over emerging indications of resistance to this class of antimalarial drugs. Several individual molecules have been proposed as targets for artemisinins, in addition to the idea that artemisinins might have many targets at the same time. Our suggestion that artemisinins inhibit the parasite-encoded sarco-endoplasmic reticulum Ca(2+)-ATPase (SERCA) PfATP6 has gained support from recent observations that a polymorphism in the gene encoding PfATP6 is associated with in vitro resistance to artemether in field isolates of P. falciparum.
40
Artemisinins target the SERCA of Plasmodium falciparum
Ursula Eckstein‐Ludwig, Richard Webb, Iris D. A. van Goethem et al. · Nature · 2003 · 1K citations
Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number
Ric N. Price, Anne‐Catrin Uhlemann, Alan Brockman et al. · The Lancet · 2004 · 839 citations
Identification of an antimalarial synthetic trioxolane drug development candidate
Jonathan L. Vennerstrom, Sarah Arbe‐Barnes, Reto Brun et al. · Nature · 2004 · 617 citations